Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 7/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | F9 | P00740 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22272502 | 0.88 | HDAC1 (0.52) | MAPTMEN1KMT2ACLK1CHRNA7 | |
| SCHEMBL999671 | 0.87 | HDAC1 (0.56) | MAPTMEN1KMT2ACLK1ALDH1A1 | |
| SCHEMBL23466533 | 0.84 | CLK1 (0.43) | MAPTMEN1KMT2ACLK1DYRK1A | |
| SCHEMBL1000816 | 0.83 | PTPN2 (0.49) | MAPTMEN1KMT2ACLK1DYRK1A | |
| SCHEMBL3342502 | 0.83 | BCL2L1 (0.59) | MAPTMEN1KMT2ACLK1DYRK1A | |
| SCHEMBL3641925 | 0.82 | DYRK1A (0.68) | MAPTMEN1KMT2ACLK1DYRK1A | |
| SCHEMBL31108990 | 0.82 | MEN1 (0.64) | MAPTMEN1KMT2ACLK1DYRK1A | |
| SCHEMBL2895953 | 0.82 | MEN1 (0.64) | MAPTMEN1KMT2ACLK1DYRK1A | |
| SCHEMBL15697489 | 0.82 | HDAC1 (0.61) | MAPTMEN1KMT2ACLK1DYRK1A | |
| Hydrochloric Acid SCHEMBL6983330 | 0.82 | PTPN2 (0.48) | MAPTMEN1KMT2ACLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036587-A | Zalutst compound and application thereof in inhibiting MLL1-WDR5 interaction | 暨南大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | PHEON THERAPEUTICS LTD (GB) | 2025-01-09 | — | — | US | disclosed |
| EP-4441033-A1 | NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118715206-A | Novel HDAC inhibitors and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | STERIX LIMITED (GB) | 2005-10-13 | — | — | US | disclosed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
| WO-2005042513-A1 | PHENYL CARBOXAMIDE AND SULFONAMIDE DERIVATIVES FOR USE AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE | STERIX LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| US-20040142953-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20040106599-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2004-06-03 | — | — | US | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
| US-5863936-A | HETEROCYCLIC ENZYME INHIBITORS AS ANTICANCER AGENTS | GERON CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106599-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MAPT 2110/4885MEN1 2635/4885KMT2A 52/4885 |
| US-20050227987-A1 | 11beta-hydroxysteroid dehydrogenase inhibitors | HSD3B1, HSD3B2, HSD17B3 | MAPT 4512/4885MEN1 2978/4885KMT2A 1973/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | MAPT 3224/4885MEN1 2948/4885KMT2A 2380/4885 |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | CCND2, BRD2, CCND3 | MAPT 4580/4885MEN1 2837/4885KMT2A 2763/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | MAPT 2829/4885MEN1 3551/4885KMT2A 97/4885 |
| US-20040142953-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | MAPT 2110/4885MEN1 2635/4885KMT2A 52/4885 |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | HDAC1, HDAC7, HDAC5 | MAPT 2829/4885MEN1 3551/4885KMT2A 97/4885 |
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | MAPT 2607/4885MEN1 2925/4885KMT2A 45/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | MAPT 2106/4885MEN1 2336/4885KMT2A 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.